Bare Lymphocyte Syndrome Type 2 (BLS2) / MHC Class II Deficiency — a rare autosomal recessive primary immunodeficiency caused by mutations in any of four regulatory genes encoding the transcription factor complex required for constitutive MHC class II expression on antigen-presenting cells: RFXANK (regulatory factor X-associated ankyrin-containing protein), RFX5 (regulatory factor X 5), RFXAP (regulatory factor X-associated protein), or CIITA (class II major histocompatibility complex transactivator), the non-DNA-binding coactivator that recruits RNA polymerase II to MHC class II gene promoters and whose mutations constitute the most frequent genetic cause of BLS2; with the pathophysiological consequence that antigen-presenting cells including dendritic cells, macrophages, B cells, and thymic epithelium fail to express HLA-DP, HLA-DQ, and HLA-DR — the MHC class II molecules that present extracellular antigen-derived peptides to CD4+ helper T cells and that constitute the positive selection signal that allows CD4+ T cells to complete development in the thymic medulla — producing a combined immunodeficiency whose cellular mechanism operates at the level of thymic CD4+ T-cell selection: CD4+ thymocytes that cannot find their cognate selecting ligand (the MHC class II-peptide complex on cortical epithelium) undergo apoptosis during thymic positive selection, resulting in severe peripheral CD4+ T-cell lymphopenia despite the presence of structurally normal lymphocytes in circulation (the "bare lymphocyte" designation reflecting that the circulating lymphocytes lack MHC class II expression on B cells and antigen-presenting cells, not that lymphocyte numbers are absent — distinguishing BLS2 from other SCIDs by the unusual feature of normal or near-normal total lymphocyte counts with severely reduced CD4+ T-cell subset despite apparently adequate lymphocyte numbers on CBC); presenting predominantly in children of North African Arab descent with a particularly high prevalence in Moroccan, Algerian, Tunisian, and Middle Eastern populations where founder mutations in RFXANK are well-characterized, though cases have been described across ethnicities; with clinical presentation of recurrent respiratory tract infections (recurrent otitis media, sinopulmonary infections with encapsulated bacteria, recurrent pneumonia with Streptococcus pneumoniae and Haemophilus influenzae), severe gastrointestinal infections (cryptosporidium diarrhea — a clinically distinctive pathogen causing chronic profuse watery diarrhea and progressive biliary tract disease in BLS2 — Giardia, rotavirus, enteric bacteria), Enterovirus and CMV susceptibility reflecting the absent cellular immunity, and failure to thrive due to chronic diarrhea and malabsorption; the hepatic complication of sclerosing cholangitis caused by chronic Cryptosporidium biliary invasion constituting a clinically important and distinctive complication of BLS2 that can lead to biliary stricturing, cholestasis, secondary hepatic dysfunction, and cirrhosis; distinguished from other combined immunodeficiency forms by the paradox of a normal total lymphocyte count with absent CD4+ T-cell function, requiring CD4/CD8 subset analysis to reveal the selective CD4+ lymphopenia that is otherwise invisible on CBC; treated definitively with hematopoietic stem cell transplantation as the only curative approach, with HSCT outcomes in BLS2 reported as modestly less favorable than in SCID-X1 or RAG SCID due to the typically later age at diagnosis, accumulated organ damage particularly hepatic sclerosing cholangitis, and the conditioning toxicity in patients with pre-existing malnutrition and hepatic compromise.
Bare Lymphocyte Syndrome Type 2 technology platforms — whether serving pediatric immunology programs diagnosing BLS2 from the paradoxical combination of normal or elevated total lymphocyte counts with profoundly reduced CD4+ T cells and recurrent respiratory and GI infections, platforms coordinating flow cytometric confirmation of absent MHC class II expression on monocytes and B cells (the functional diagnostic test that directly demonstrates the core molecular defect distinguishing BLS2 from other CD4+ lymphopenic conditions), RFXANK/RFX5/RFXAP/CIITA gene sequencing platforms including founder mutation panels for North African Arab populations, HSCT programs coordinating donor matching and pre-conditioning management that must account for pre-existing hepatic sclerosing cholangitis, hepatic function impairment from Cryptosporidium biliary disease, and malnutrition when selecting conditioning regimens, infection management platforms coordinating Cryptosporidium treatment and biliary decompression in patients with sclerosing cholangitis, CD4+ T-cell count monitoring platforms tracking the specific CD4+ lymphopenia (with total lymphocyte count misleadingly normal) over the pre-HSCT management period and through post-transplant CD4+ reconstitution, immunoglobulin replacement management platforms tracking IgG supplementation through IVIG or SCIG until post-HSCT humoral reconstitution, hepatic sclerosing cholangitis surveillance platforms tracking biliary anatomy, liver function, and cholestasis severity through the HSCT period and beyond, nutritional support monitoring platforms managing growth failure and malnutrition rehabilitation in a population with chronic diarrhea and malabsorption, and infection frequency log platforms documenting the recurrent respiratory and GI infection rate before and after HSCT as the primary efficacy metric for transplant success — must maintain the availability and performance that CD4+ lymphopenia monitoring, MHC class II expression surveillance, Cryptosporidium management coordination, hepatic sclerosing cholangitis tracking, and HSCT engraftment surveillance impose. This guide explains why BLS2 tech platforms require specialized monitoring, what to monitor, and how to build a monitoring strategy calibrated to the paradoxical immunophenotype, hepatic complication burden, and complex HSCT management of modern Bare Lymphocyte Syndrome Type 2 care.
Why Bare Lymphocyte Syndrome Type 2 Tech Platforms Require Specialized Monitoring Attention
BLS2 platform monitoring demands are shaped by the diagnostic paradox that causes delayed diagnosis, the cryptosporidium hepatobiliary complication that drives pre-HSCT morbidity, and the complex HSCT management in patients with accumulated organ damage that distinguishes BLS2 from the other SCID forms where earlier diagnosis through newborn screening allows pre-symptomatic transplant before significant infection-related organ damage.
CD4+ T-cell count monitoring is the diagnostic anchor for a paradoxically lymphocyte-count-normal immunodeficiency. The most common cause of diagnostic delay in BLS2 is the normal total lymphocyte count on CBC that provides false reassurance during the recurrent infection workup — the selective CD4+ T-cell lymphopenia is invisible until a lymphocyte subset panel with CD4/CD8 analysis is performed. Platforms that coordinate CD4+ count monitoring must display the absolute CD4+ count prominently against age-appropriate reference ranges and flag selective CD4+ lymphopenia even in the context of normal total lymphocyte counts. Monitor during clinical hours with alert thresholds calibrated to the selective CD4+ depletion pattern.
MHC class II expression flow cytometry platforms confirm the molecular diagnosis and distinguish BLS2 from other CD4-lymphopenic conditions. The definitive diagnostic test for BLS2 — demonstrating absent HLA-DR expression on CD19+ B cells and CD14+ monocytes by flow cytometry — is not a routine clinical immunology assay and requires specialized laboratory capability. Platforms coordinating this specialized testing must maintain the laboratory ordering and result reporting pathways that enable this confirmatory test. Monitor during laboratory processing hours.
Cryptosporidium and hepatic sclerosing cholangitis management platforms track the defining complication of BLS2. Cryptosporidium parvum biliary infection in BLS2 produces sclerosing cholangitis — a chronic biliary inflammatory and fibrotic process with irregular intrahepatic and extrahepatic bile duct stricturing, progressive cholestasis, and risk of biliary cirrhosis — that is both the most clinically significant long-term complication of BLS2 before transplant and a major determinant of HSCT outcomes since pre-transplant hepatic sclerosing cholangitis affects conditioning regimen selection (hepatotoxic conditioning agents are contraindicated in patients with significant pre-existing hepatic disease) and post-transplant hepatic recovery. Platforms monitoring biliary anatomy, hepatic function, stool Cryptosporidium, and cholestasis severity are the management infrastructure for the complication that most distinguishes BLS2 from other SCID forms. Monitor during clinical hours with immediate alerting on acute hepatic decompensation parameters.
HSCT engraftment in BLS2 requires tracking CD4+ T-cell reconstitution specifically. Post-HSCT immune reconstitution in BLS2 is measured primarily by CD4+ T-cell count recovery — the specific lymphocyte subset that is absent due to absent MHC class II-mediated thymic selection — in a context where total lymphocyte count may have been normal before transplant and where CD4+ reconstitution trajectories post-HSCT determine when infection prophylaxis can be weaned and when immune competence is restored. Monitor CD4+ reconstitution platforms at 1-minute intervals during clinical hours.
What to Monitor on a Bare Lymphocyte Syndrome Type 2 Tech Platform
CD4+ T-Cell Count Monitoring and Lymphocyte Subset Analysis
Monitor absolute CD4+ T-cell count records at each clinical assessment with age-appropriate reference range annotation and selective CD4+ lymphopenia alert flagging (CD4+ count below 200/μL or below 20% of total lymphocytes in children with normal total lymphocyte counts should flag as clinically significant regardless of normal CBC), CD4/CD8 ratio records (inverted ratio with CD8 predominance characteristic of BLS2), CD8+ cytotoxic T-cell count records (normal or elevated in BLS2 as CD8+ thymocytes use MHC class I for positive selection, which proceeds normally), CD19+ B-cell count records (normal B-cell counts in BLS2), NK cell count records (normal), total lymphocyte count records with prominent notation that normal total lymphocyte count does not exclude BLS2, CD4+ count trend visualization records across the diagnostic and pre-HSCT monitoring period, and post-HSCT CD4+ reconstitution trajectory records comparing individual patient recovery against post-HSCT normative curves. Monitor at 1-minute intervals during clinical hours.
MHC Class II Expression Confirmation Testing
Monitor HLA-DR expression flow cytometry records on CD19+ B cells and CD14+ monocytes (HLA-DR absent or severely reduced in BLS2; normal HLA-DR expression excludes BLS2), HLA-DP and HLA-DQ expression records confirming absence of all MHC class II isotypes, specialized laboratory ordering coordination records for the MHC class II expression panel (confirming laboratory with appropriate expertise has received order), result reporting records with turnaround time tracking, and repeat testing records for patients in whom the expression assay was performed during an inflammatory episode (where cytokine-driven MHC class II upregulation may partially normalize expression). Alert on sustained platform failures during laboratory processing hours.
RFXANK/RFX5/RFXAP/CIITA Genetic Testing
Monitor gene sequencing order records (coordinating testing prioritization based on clinical suspicion and ethnic background — RFXANK founder mutations dominate in North African Arab populations justifying targeted RFXANK testing before full panel), variant interpretation records with functional classification (pathogenic/likely pathogenic/VUS), founder mutation screening records for families of North African Arab descent (RFXANK splice-site mutations at c.IVS7-1G>C and c.IVS8+1G>C predominant in Moroccan and Algerian families), family cascade genetic testing records for parents (obligate heterozygous carriers), cascade testing records for siblings, and genetic counseling session records documenting the 25% autosomal recessive recurrence risk and carrier screening recommendations. Monitor during business hours.
Cryptosporidium Infection Management and Surveillance
Monitor stool Cryptosporidium antigen or PCR records at each GI symptom presentation, treatment records for Cryptosporidium (nitazoxanide as the preferred agent though effectiveness is limited in T-cell-deficient patients without immune reconstitution; paromomycin as alternative), stool frequency and consistency records documenting diarrhea severity (Cryptosporidium diarrhea in BLS2 can reach 10–20 watery stools per day), dehydration assessment records, electrolyte monitoring records (sodium, potassium, bicarbonate during acute diarrheal episodes), Cryptosporidium biliary drainage platform records when endoscopic or percutaneous biliary interventions are performed to decompress sclerosing cholangitis strictures, and microsporidia co-infection surveillance records (another intracellular GI pathogen causing diarrhea in T-cell-deficient patients). Alert on sustained failures during clinical hours.
Hepatic Sclerosing Cholangitis Surveillance
Monitor liver function test records at each clinical visit (ALT, AST, GGT, alkaline phosphatase, bilirubin — GGT and alkaline phosphatase elevation disproportionate to transaminases characteristic of biliary disease), gamma-glutamyl transferase trajectory records as the most sensitive marker of biliary involvement, total and direct bilirubin records (direct hyperbilirubinemia indicating cholestasis), albumin and pre-albumin records (hypoalbuminemia reflecting both hepatic synthetic dysfunction and protein loss from GI tract), MRCP or liver ultrasound records documenting biliary anatomy (irregular bile duct caliber changes, peribiliary fibrosis, intrahepatic duct dilatation), liver biopsy records for staging hepatic fibrosis when biliary abnormalities are progressive, portal hypertension monitoring records (splenomegaly, platelet count, Doppler portal vein flow on ultrasound), hepatic function Child-Pugh or PELD/PELD-NA score records for pre-HSCT hepatic risk stratification, and post-HSCT hepatic function recovery records tracking biliary improvement after immune reconstitution (when Cryptosporidium is cleared by reconstituted CD4+ T cells). Alert immediately on acute hepatic decompensation parameters.
Nutritional Support and Growth Monitoring
Monitor weight records at each visit with weight-for-age Z-score calculation, length/height records with height-for-age Z-score, head circumference records in infants, body mass index records for older children, serum albumin and pre-albumin records as nutritional markers, zinc and micronutrient levels in patients with chronic diarrhea and malabsorption, caloric intake records and dietitian assessment records, nasogastric or gastrostomy tube feeding records for patients requiring enteral nutritional supplementation, parenteral nutrition records for patients with severe malabsorptive diarrhea, and growth velocity trend visualization records comparing pre- and post-HSCT growth trajectories. Alert on sustained failures during business hours — nutritional monitoring is the pre-HSCT optimization platform for patients whose conditioning tolerance depends on nutritional rehabilitation.
IVIG and Infection Prophylaxis Management
Monitor IVIG infusion scheduling records with IgG trough monitoring (target above 500–800 mg/dL to supplement the deficient humoral immunity), IVIG dose and infusion rate records, TMP-SMX Pneumocystis prophylaxis scheduling records, antifungal prophylaxis records, CMV surveillance records (monthly CMV PCR during pre-HSCT period and during post-transplant immunosuppression), infection frequency log records documenting recurrent respiratory and GI infection episodes before and after HSCT (the primary clinical outcome measure for BLS2 HSCT efficacy), and live vaccine contraindication flags on all BLS2 patient records until immune reconstitution is formally documented. Alert during clinical hours.
HSCT Pre-Conditioning and Engraftment Surveillance
Monitor hepatic function pre-conditioning assessment records determining conditioning regimen selection (fludarabine-based reduced-intensity conditioning preferred in patients with significant hepatic sclerosing cholangitis to reduce hepatotoxic conditioning burden), conditioning toxicity records including mucositis, hepatic veno-occlusive disease assessment, and infection events during aplasia, stem cell infusion records, post-HSCT CD4+ T-cell reconstitution records at day +30, +60, +100, +180, +365 timepoints, donor chimerism records in T-cell and B-cell compartments, MHC class II expression reconstitution records confirming that donor-derived antigen-presenting cells express HLA-DR on B cells and monocytes post-HSCT (restoration of MHC class II expression is the molecular evidence of HSCT cure), and infection prophylaxis weaning protocol records documenting sequential discontinuation of TMP-SMX, antifungals, and IVIG as CD4+ counts and immunoglobulin independence are established. Monitor during all conditioning and early post-HSCT periods.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. BLS2 management coordinates across pediatric immunology, HSCT, hepatology (sclerosing cholangitis management), gastroenterology (Cryptosporidium diarrhea and malabsorption), clinical nutrition, infectious disease, and radiology (MRCP, liver ultrasound) — authentication failures interrupt the multidisciplinary access required for a condition where hepatic complication severity directly determines HSCT conditioning intensity and timing.
SSL Certificates
Monitor SSL certificate expiry across immunophenotyping portals, MHC class II expression laboratory systems, HSCT coordination and engraftment surveillance platforms, hepatic sclerosing cholangitis monitoring dashboards, nutritional support tracking systems, and infection prophylaxis coordination portals. Certificate errors during laboratory result transmission or HSCT coordination sessions interrupt time-sensitive clinical management.
HIPAA and BLS2 Genetic Data Privacy Considerations
BLS2 technology platforms handle PHI including RFXANK/RFX5/RFXAP/CIITA biallelic pathogenic variant records with autosomal recessive recurrence implications, hepatic sclerosing cholangitis records documenting a chronic liver complication with long-term disability and transplant implications, Cryptosporidium infection records that may carry stigma in some cultural contexts, comprehensive nutritional failure records documenting pediatric growth failure, and HSCT records including donor information. For North African Arab populations where BLS2 is relatively more prevalent, platforms must apply culturally appropriate privacy protections and support family cascade screening programs that may encounter consanguinity-related privacy sensitivities. HIPAA Security Rule protections apply across all platform components with particular attention to genetic testing data and hepatic disease records given the long-term insurance and disability implications.
Alerting Strategy for BLS2 Tech Platforms
Immediate 24/7 alerting: Authentication; acute hepatic decompensation alerts (bilirubin, INR, ammonia threshold alerts for patients with significant pre-existing hepatic disease).
Immediate clinical-hours alerting: CD4+ T-cell count monitoring with selective CD4+ lymphopenia flags; MHC class II expression flow cytometry result reporting; unexpected CD4+ count decline during HSCT reconstitution period.
Immediate alerting during acute complications: Acute Cryptosporidium diarrhea with dehydration or electrolyte abnormality records; acute cholangitis or biliary decompensation events.
Sustained-failure alerting (10–15 minutes): Hepatic sclerosing cholangitis surveillance platforms; nutritional support monitoring; IVIG and prophylaxis coordination; HSCT chimerism surveillance.
30-day advance warning: SSL certificates across all domains.
Vigilmon's multi-region monitoring confirms BLS2 platform availability from the geographies where BLS2 is most prevalent — North African, Middle Eastern, and other populations with founder RFXANK mutations — and where concentrated pediatric immunology, HSCT, and hepatobiliary specialist expertise for this rare condition exists, ensuring that monitoring coverage matches the geographic distribution of patients and the institutional concentration of clinical expertise.
Status Page for BLS2 Care Team Communication
A real-time status page gives pediatric immunologists reviewing CD4+ lymphopenia trends, hepatologists tracking sclerosing cholangitis progression, HSCT coordinators monitoring engraftment chimerism, gastroenterologists managing Cryptosporidium diarrhea, nutritionists tracking growth rehabilitation, infectious disease specialists coordinating prophylaxis, and families managing a child with one of the most clinically complex and diagnostically delayed primary immunodeficiencies immediate platform visibility without requiring IT support contact.
Include the status page URL in BLS2 family education materials, HSCT coordination emergency procedures, hepatic sclerosing cholangitis after-hours management contacts, and nutritional support coordination fallback procedures.
Vigilmon Setup for Bare Lymphocyte Syndrome Type 2 Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | Hepatic decompensation alerts (bilirubin, INR thresholds) | 1 min | Slack + PagerDuty (24/7) | | CD4+ T-cell count / selective lymphopenia monitoring | 1 min | Slack + PagerDuty (clinical hours) | | MHC class II expression testing platform | 1 min | Slack + PagerDuty (lab processing hours) | | HSCT CD4+ engraftment reconstitution | 1 min | Slack + PagerDuty (clinical hours) | | Hepatic sclerosing cholangitis surveillance (LFTs, MRCP) | 2 min | Slack (business hours) | | Cryptosporidium infection monitoring | 2 min | Slack (clinical hours) | | Nutritional support and growth monitoring | 2 min | Slack (business hours) | | IVIG scheduling and IgG trough monitoring | 2 min | Slack (clinical hours) | | TMP-SMX and antifungal prophylaxis coordination | 2 min | Slack (clinical hours) | | CMV surveillance (monthly PCR) | 2 min | Slack (business hours) | | RFXANK/RFX5/RFXAP/CIITA genetic testing platform | 2 min | Slack (business hours) | | Patient portal / family communication | 2 min | Slack (extended hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 PagerDuty alerting
- Configure hepatic decompensation threshold alerts with 24/7 immediate alerting
- Add CD4+ T-cell count monitoring with immediate clinical-hours alerting and selective CD4+ lymphopenia flags
- Configure MHC class II expression flow cytometry platforms with immediate clinical-hours alerting
- Add HSCT CD4+ engraftment reconstitution monitoring with immediate clinical-hours alerting
- Configure hepatic sclerosing cholangitis surveillance with sustained-failure alerting during business hours
- Add Cryptosporidium infection monitoring with sustained-failure alerting during clinical hours
- Configure nutritional support and growth monitoring with sustained-failure alerting during business hours
- Add IVIG and infection prophylaxis coordination with sustained-failure alerting during clinical hours
- Configure RFXANK/RFX5/RFXAP/CIITA genetic testing platforms with sustained-failure alerting
- Enable SSL certificate monitoring across all immunology, hepatology, HSCT, and genetic testing platforms
- Add the status page URL to family materials, HSCT emergency procedures, and hepatic sclerosing cholangitis management contacts
Conclusion
Bare Lymphocyte Syndrome Type 2 platforms carry the monitoring obligation for a condition whose clinical course is defined by the accumulated damage from delayed diagnosis — where the paradox of a normal total lymphocyte count in a child with absent CD4+ T-cell function means that weeks to months of recurrent respiratory infections, chronic cryptosporidium diarrhea, protein-losing enteropathy, and progressive biliary sclerosing cholangitis have accumulated before the diagnosis is established and the HSCT pathway initiated, where platform failures during this pre-diagnosis and pre-transplant period directly prolong diagnostic uncertainty, delay Cryptosporidium biliary management, and allow hepatic sclerosing cholangitis to progress; where a CD4+ monitoring platform unavailable at the initial immunology evaluation of an eighteen-month-old North African Arab girl who has had four episodes of pneumococcal otitis media and is failing to thrive with a total lymphocyte count of 2,800/μL — apparently reassuring — means the pediatric immunologist cannot review the flow cytometry that would show CD4+ counts of 35/μL against an age-appropriate normal of above 1,000/μL, cannot access the CD4/CD8 ratio that at 0.06 is diagnostic of a selective CD4 aplasia, cannot order the MHC class II expression panel that would confirm absent HLA-DR on B cells within 48 hours, and instead discharges the child without diagnosis for another two months while Cryptosporidium parvum colonizes her biliary tree; where a hepatic sclerosing cholangitis surveillance platform unavailable in the month before HSCT means the HSCT team cannot retrieve the GGT trending at 4 times the upper limit of normal, cannot review the MRCP showing progressive intrahepatic biliary stricturing that has advanced from mild beading to multifocal stricturing in six months, and cannot document the Child-Pugh score that would mandate switching from myeloablative to reduced-intensity conditioning to avoid conditioning-related hepatotoxicity in a patient whose liver cannot safely tolerate full-dose busulfan; where a post-HSCT CD4+ reconstitution platform unavailable at the six-month post-transplant visit means the immunologist cannot show the family that CD4+ counts have risen from undetectable at transplant to 240/μL at month six, cannot document the HLA-DR re-expression on B cells confirming donor-derived antigen-presenting cell engraftment, and cannot initiate the TMP-SMX weaning protocol that would allow a two-year-old girl to stop twice-daily antibiotic prophylaxis she has been receiving for eight months; and where a biliary surveillance platform unavailable at the twelve-month post-HSCT hepatology visit means the hepatologist cannot compare the post-transplant MRCP to the pre-transplant baseline to assess whether biliary stricturing has stabilized, progressed, or partially resolved with Cryptosporidium clearance by reconstituted CD4+ T cells — the most clinically important imaging comparison of the entire post-HSCT monitoring program for a BLS2 patient whose long-term hepatic function depends on whether sclerosing cholangitis progression is arrested by immune reconstitution or continues toward biliary cirrhosis despite transplant. Platform failures at each of these junctures are not delayed deliverables. They are disruptions in the diagnostic pathway, pre-HSCT optimization, conditioning regimen selection, and post-HSCT immune reconstitution documentation for a condition where every accumulated week of CD4+ lymphopenia without intervention means additional Cryptosporidium biliary exposure and additional hepatic sclerosing cholangitis progression.
Uptime monitoring gives BLS2 tech teams the detection capability to identify platform failures within seconds, maintain clinical downtime procedures that preserve CD4+ monitoring continuity, hepatic surveillance access, and HSCT coordination during outages, and demonstrate to pediatric immunology programs, HSCT centers, hepatobiliary specialists, genetic counselors, and families that platform reliability matches the diagnostic urgency, pre-transplant stabilization complexity, and long-term hepatic surveillance requirements of modern Bare Lymphocyte Syndrome Type 2 care.
Start monitoring your BLS2 care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #BareLymphocyteSyndrome #BLS2 #MHCClassII #HLAClass2 #RFXANK #CIITA #CD4lymphopenia #primaryImmunodeficiency #HSCT #Cryptosporidium #sclerosingCholangitis #NorthAfrican #pediatricImmunology #IVIG #HIPAA #healthtech #digitalhealth #uptime #sre